脐带血NK细胞治疗肝癌的临床应用
Clinical Application of Umbilical Cord Blood NK Cells in the Treatment of Liver Cancer
DOI: 10.12677/jcpm.2024.34324, PDF,   
作者: 吴春涛*, 吴 庆, 詹琪琪, 许雅贤, 张 祎：华北理工大学附属医院甲状腺外科二科，河北 唐山
关键词: 肝癌；自然杀伤细胞；脐带血；免疫疗法；Liver Cancer； Natural Killer Cells； Umbilical Cord Blood； Immunotherapy
摘要: 肝癌是全球癌症相关死亡的主要原因之一，尤其在中国，其高发病率和死亡率对公共卫生构成了巨大挑战。随着免疫疗法在恶性肿瘤治疗领域的不断发展，自然杀伤细胞(Natural Killer Cell, NK细胞)因其独特的非MHC依赖性抗肿瘤机制，成为研究的热点。其中，脐带血(Umbilical Cord Blood, UCB)来源的NK细胞(UCB-NK细胞)以其高增殖潜力、低移植物抗宿主病风险和便捷的来源，展现出独特优势。本文综述了肝癌的流行病学特点及NK细胞在免疫治疗中的作用机制，重点探讨了UCB-NK细胞的生物学特性及其在肝癌治疗中的研究进展。研究表明，通过适当的体内外刺激，UCB-NK细胞可显著增强抗肿瘤活性，并在与传统治疗方法如化疗、局部消融术和不可逆电穿孔术联合应用中展现出协同效应。多项临床试验显示，UCB-NK细胞疗法在安全性和疗效方面均具备广阔的应用前景。本文旨在为未来基于UCB-NK细胞的肝癌免疫治疗研究提供理论依据和新思路。
Abstract: Liver cancer is one of the leading causes of cancer-related mortality worldwide, particularly in China, where its high incidence and mortality rates pose significant public health challenges. With the ongoing advancements in immunotherapy for malignant tumors, natural killer (NK) cells have gained considerable attention due to their unique non-MHC-dependent antitumor mechanisms. Among them, umbilical cord blood (UCB)-derived NK cells (UCB-NK cells) have demonstrated distinctive advantages, including high proliferation potential, low risk of graft-versus-host disease, and convenient availability. This review summarizes the epidemiological characteristics of liver cancer and the mechanisms of NK cells in immunotherapy, with a focus on the biological properties of UCB-NK cells and their therapeutic progress in liver cancer. Studies have shown that appropriately stimulated UCB-NK cells, both in vitro and in vivo, significantly enhance antitumor activity and exhibit synergistic effects when combined with traditional treatments such as chemotherapy, local ablation, and irreversible electroporation. Multiple clinical trials have revealed the promising safety and efficacy of UCB-NK cell therapy, highlighting its broad potential for clinical application. This review aims to provide a theoretical basis and novel insights for future research on UCB-NK cell-based immunotherapy for liver cancer.
文章引用：吴春涛, 吴庆, 詹琪琪, 许雅贤, 张祎. 脐带血NK细胞治疗肝癌的临床应用[J]. 临床个性化医学, 2024, 3(4): 2277-2283. https://doi.org/10.12677/jcpm.2024.34324

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Cao, M.D., Wang, H., Shi, J.F., et al. (2020) Disease Burden of Liver Cancer in China: An Updated and Integrated Analysis on Multi-Data Source Evidence. Chinese Journal of Epidemiology, 41, 1848-1858.
[3] Liu, S., Galat, V., Galat4, Y., Lee, Y.K.A., Wainwright, D. and Wu, J. (2021) NK Cell-Based Cancer Immunotherapy: From Basic Biology to Clinical Development. Journal of Hematology & Oncology, 14, Article No. 7. [Google Scholar] [CrossRef] [PubMed]
[4] Laskowski, T.J., Biederstädt, A. and Rezvani, K. (2022) Natural Killer Cells in Antitumour Adoptive Cell Immunotherapy. Nature Reviews Cancer, 22, 557-575. [Google Scholar] [CrossRef] [PubMed]
[5] Chu, J., Gao, F., Yan, M., Zhao, S., Yan, Z., Shi, B., et al. (2022) Natural Killer Cells: A Promising Immunotherapy for Cancer. Journal of Translational Medicine, 20, Article No. 240. [Google Scholar] [CrossRef] [PubMed]
[6] Shin, M.H., Kim, J., Lim, S.A., Kim, J., Kim, S. and Lee, K. (2020) NK Cell-Based Immunotherapies in Cancer. Immune Network, 20, e14. [Google Scholar] [CrossRef] [PubMed]
[7] Myers, J.A. and Miller, J.S. (2020) Exploring the NK Cell Platform for Cancer Immunotherapy. Nature Reviews Clinical Oncology, 18, 85-100. [Google Scholar] [CrossRef] [PubMed]
[8] Imai, K., Matsuyama, S., Miyake, S., Suga, K. and Nakachi, K. (2000) Natural Cytotoxic Activity of Peripheral-Blood Lymphocytes and Cancer Incidence: An 11-Year Follow-Up Study of a General Population. The Lancet, 356, 1795-1799. [Google Scholar] [CrossRef] [PubMed]
[9] Cheng, M., Chen, Y., Xiao, W., Sun, R. and Tian, Z. (2013) NK Cell-Based Immunotherapy for Malignant Diseases. Cellular & Molecular Immunology, 10, 230-252. [Google Scholar] [CrossRef] [PubMed]
[10] Zhao, X., Cai, L., Hu, Y. and Wang, H. (2020) Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer. Frontiers in Immunology, 11, Article 584099. [Google Scholar] [CrossRef] [PubMed]
[11] Herrera, L., Santos, S., Vesga, M.A., Anguita, J., Martin-Ruiz, I., Carrascosa, T., et al. (2019) Adult Peripheral Blood and Umbilical Cord Blood NK Cells Are Good Sources for Effective CAR Therapy against CD19 Positive Leukemic Cells. Scientific Reports, 9, Article No. 18729. [Google Scholar] [CrossRef] [PubMed]
[12] Sarvaria, A., Jawdat, D., Madrigal, J.A. and Saudemont, A. (2017) Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications. Frontiers in Immunology, 8, Article 329. [Google Scholar] [CrossRef] [PubMed]
[13] Dalle, J., Menezes, J., Wagner, É., Blagdon, M., Champagne, J., Champagne, M.A., et al. (2005) Characterization of Cord Blood Natural Killer Cells: Implications for Transplantation and Neonatal Infections. Pediatric Research, 57, 649-655. [Google Scholar] [CrossRef] [PubMed]
[14] Lin, Y., Zheng, L., Fang, K., Zheng, Y., Wu, J. and Zheng, M. (2023) Proportion of Liver Cancer Cases and Deaths Attributable to Potentially Modifiable Risk Factors in China. International Journal of Epidemiology, 52, 1805-1814. [Google Scholar] [CrossRef] [PubMed]
[15] Wei, Q., Zhou, H., Hou, X., Liu, X., Chen, S., Huang, X., et al. (2022) Current Status of and Barriers to the Treatment of Advanced-Stage Liver Cancer in China: A Questionnaire-Based Study from the Perspective of Doctors. BMC Gastroenterology, 22, Article No. 351. [Google Scholar] [CrossRef] [PubMed]
[16] Shan, T., Ran, X., Li, H., Feng, G., Zhang, S., Zhang, X., et al. (2023) Disparities in Stage at Diagnosis for Liver Cancer in China. Journal of the National Cancer Center, 3, 7-13. [Google Scholar] [CrossRef] [PubMed]
[17] Albinger, N., Hartmann, J. and Ullrich, E. (2021) Current Status and Perspective of CAR-T and CAR-NK Cell Therapy Trials in Germany. Gene Therapy, 28, 513-527. [Google Scholar] [CrossRef] [PubMed]
[18] Abel, A.M., Yang, C., Thakar, M.S. and Malarkannan, S. (2018) Natural Killer Cells: Development, Maturation, and Clinical Utilization. Frontiers in Immunology, 9, Article 1869. [Google Scholar] [CrossRef] [PubMed]
[19] Damele, L., Spaggiari, G.M., Parodi, M., Mingari, M.C., Vitale, M. and Vitale, C. (2022) Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More than a Promise? Cancers, 14, Article 4439. [Google Scholar] [CrossRef] [PubMed]
[20] Chan, I.S. and Ewald, A.J. (2022) The Changing Role of Natural Killer Cells in Cancer Metastasis. Journal of Clinical Investigation, 132, e143762. [Google Scholar] [CrossRef] [PubMed]
[21] Trinchieri, G. (1989) Biology of Natural Killer Cells. Advances in Immunology, 47, 187-376. [Google Scholar] [CrossRef] [PubMed]
[22] Campbell, K.S. and Hasegawa, J. (2013) Natural Killer Cell Biology: An Update and Future Directions. Journal of Allergy and Clinical Immunology, 132, 536-544. [Google Scholar] [CrossRef] [PubMed]
[23] Wu, S., Fu, T., Jiang, Y. and Shao, Z. (2020) Natural Killer Cells in Cancer Biology and Therapy. Molecular Cancer, 19, Article No. 120. [Google Scholar] [CrossRef] [PubMed]
[24] Montaldo, E., Vitale, C., Cottalasso, F., Conte, R., Glatzer, T., Ambrosini, P., et al. (2012) Human NK Cells at Early Stages of Differentiation Produce CXCL8 and Express CD161 Molecule That Functions as an Activating Receptor. Blood, 119, 3987-3996. [Google Scholar] [CrossRef] [PubMed]
[25] Shokouhifar, A., Anani Sarab, G., Yazdanifar, M., Fereidouni, M., Nouri, M. and Ebrahimi, M. (2021) Overcoming the UCB HSCs—Derived NK Cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways. Cancer Cell International, 21, Article No. 298. [Google Scholar] [CrossRef] [PubMed]
[26] Zhang, Y., Zhou, W., Yang, J., Yang, J. and Wang, W. (2023) Chimeric Antigen Receptor Engineered Natural Killer Cells for Cancer Therapy. Experimental Hematology & Oncology, 12, Article No. 70. [Google Scholar] [CrossRef] [PubMed]
[27] Nguyen, S., Kuentz, M., Vernant, J., Dhedin, N., Bories, D., Debré, P., et al. (2007) Involvement of Mature Donor T Cells in the NK Cell Reconstitution after Haploidentical Hematopoietic Stem-Cell Transplantation. Leukemia, 22, 344-352. [Google Scholar] [CrossRef] [PubMed]
[28] Alnabhan, R., Madrigal, A. and Saudemont, A. (2015) Differential Activation of Cord Blood and Peripheral Blood Natural Killer Cells by Cytokines. Cytotherapy, 17, 73-85. [Google Scholar] [CrossRef] [PubMed]
[29] Escobedo-Cousin, M., Jackson, N., Laza-Briviesca, R., Ariza-McNaughton, L., Luevano, M., Derniame, S., et al. (2015) Natural Killer Cells Improve Hematopoietic Stem Cell Engraftment by Increasing Stem Cell Clonogenicity in vitro and in a Humanized Mouse Model. PLOS ONE, 10, e0138623. [Google Scholar] [CrossRef] [PubMed]
[30] Mehta, R.S., Shpall, E.J. and Rezvani, K. (2016) Cord Blood as a Source of Natural Killer Cells. Frontiers in Medicine, 2, Article 93. [Google Scholar] [CrossRef] [PubMed]
[31] Goldenson, B.H., Zhu, H., Wang, Y.M., Heragu, N., Bernareggi, D., Ruiz-Cisneros, A., et al. (2020) Umbilical Cord Blood and IPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles. Frontiers in Immunology, 11, Article 561553. [Google Scholar] [CrossRef] [PubMed]
[32] Szmania, S., Lapteva, N., Garg, T., Greenway, A., Lingo, J., Nair, B., et al. (2015) Ex vivo—Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma Patients. Journal of Immunotherapy, 38, 24-36. [Google Scholar] [CrossRef] [PubMed]
[33] Romee, R., Rosario, M., Berrien-Elliott, M.M., Wagner, J.A., Jewell, B.A., Schappe, T., et al. (2016) Cytokine-Induced Memory-Like Natural Killer Cells Exhibit Enhanced Responses against Myeloid Leukemia. Science Translational Medicine, 8, 357ra123. [Google Scholar] [CrossRef] [PubMed]
[34] Grzywacz, B., Moench, L., McKenna, D., Tessier, K.M., Bachanova, V., Cooley, S., et al. (2019) Natural Killer Cell Homing and Persistence in the Bone Marrow after Adoptive Immunotherapy Correlates with Better Leukemia Control. Journal of Immunotherapy, 42, 65-72. [Google Scholar] [CrossRef] [PubMed]
[35] Velichinskii, R.A., Streltsova, M.A., Kust, S.A., Sapozhnikov, A.M. and Kovalenko, E.I. (2021) The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors. International Journal of Molecular Sciences, 22, Article 11385. [Google Scholar] [CrossRef] [PubMed]
[36] Bae, W.K., Lee, B.C., Kim, H., Lee, J., Chung, I., Cho, S.B., et al. (2022) A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy with Hepatic Arterial Infusion Chemotherapy in Patients with Locally Advanced Hepatocellular Carcinoma. Frontiers in Immunology, 13, Article 879452. [Google Scholar] [CrossRef] [PubMed]
[37] Yang, Y., Qin, Z., Du, D., Wu, Y., Qiu, S., Mu, F., et al. (2018) Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer. CardioVascular and Interventional Radiology, 42, 48-59. [Google Scholar] [CrossRef] [PubMed]
[38] Alnaggar, M., Lin, M., Mesmar, A., Liang, S., Qaid, A., Xu, K., et al. (2018) Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome. Cellular Physiology and Biochemistry, 48, 1882-1893. [Google Scholar] [CrossRef] [PubMed]
[39] Iliopoulou, E.G., Kountourakis, P., Karamouzis, M.V., Doufexis, D., Ardavanis, A., Baxevanis, C.N., et al. (2010) A Phase I Trial of Adoptive Transfer of Allogeneic Natural Killer Cells in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Immunology, Immunotherapy, 59, 1781-1789. [Google Scholar] [CrossRef] [PubMed]
[40] Geller, M.A., Cooley, S., Judson, P.L., Ghebre, R., Carson, L.F., Argenta, P.A., et al. (2011) A Phase II Study of Allogeneic Natural Killer Cell Therapy to Treat Patients with Recurrent Ovarian and Breast Cancer. Cytotherapy, 13, 98-107. [Google Scholar] [CrossRef] [PubMed]
[41] Ruggeri, L., Mancusi, A., Capanni, M., Urbani, E., Carotti, A., Aloisi, T., et al. (2007) Donor Natural Killer Cell Allorecognition of Missing Self in Haploidentical Hematopoietic Transplantation for Acute Myeloid Leukemia: Challenging Its Predictive Value. Blood, 110, 433-440. [Google Scholar] [CrossRef] [PubMed]
[42] Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S.A., Yun, G.H., Fautsch, S.K., et al. (2005) Successful Adoptive Transfer and in vivo Expansion of Human Haploidentical NK Cells in Patients with Cancer. Blood, 105, 3051-3057. [Google Scholar] [CrossRef] [PubMed]